Perspective from Michael E. Wechsler, MD, MMSc Dupilumab was more effective than omalizumab, benralizumab and mepolizumab in treating patients with severe asthma, according to a pair of abstracts ...

Diagrammatic illustration of the mechanism of two monoclonal antibodies utilized for treating eosinophilic asthma, mepolizumab, and benralizumab. Mepolizumab specifically targets interleukin-5 (IL ...

The results of these three placebo-controlled randomized studies demonstrate that mepolizumab is efficacious ... in the production of this manuscript. Omalizumab reduces exacerbations, improves ...

Exacerbations fell with omalizumab and mepolizumab for patients with asthma and obesity. Obesity did not decrease dupilumab’s rate of response in treating asthma. Tezepelumab may address type 2 ...

Omalizumab mechanism of action. Omalizumab binds to the Ce3 domain of immunoglobulin E (lgE) and prevents free lgE from binding to the mast cell FceRI receptor. Data courtesy of Genentech ...